Bioinformatics analysis of JUP in patients with acute myocardial infarction and its potential application in clinical prognostic evaluation.

BACKGROUND

Junctional Plakoglobin (JUP) is a critical protein involved in intercellular junctions, playing a significant role in maintaining the structure and function of myocardial cells. However, the expression of JUP in acute myocardial infarction (AMI) and its potential applications in prognostic evaluation of patients remain underexplored. This study aims to investigate the expression levels of JUP in AMI patients and its association with clinical prognosis through bioinformatics analysis.

METHODS

A total of 164 patients with acute myocardial infarction admitted from January 2022 to January 2024 were selected as the study subjects. They were divided into an MACE group and a non-MACE group based on the occurrence of adverse prognostic events. Clinical data and myocardial tissue samples from patients post-percutaneous coronary intervention (PCI) were collected. The expression levels of JUP in myocardial tissue were assessed using quantitative real-time PCR (qPCR), and the functional role of the JUP gene in the prognosis of acute myocardial infarction was analyzed. The impact of JUP expression levels on the prognosis of AMI patients was evaluated using Kaplan-Meier method and Cox Proportional Hazards Model.

RESULTS

The expression level of JUP in the MACE group was significantly lower than that in the Non-MACE group ( < 0.05). The results of the Cox Proportional Hazards Model further indicated that TnI levels (HR = 12.512, 95% CI: 1.622-96.507,  < 0.05), multi-vessel disease (HR = 0.300, 95% CI: 0.108-0.834,  < 0.05), and myocardial JUP levels (HR = 0.234, 95% CI: 0.065-0.846,  < 0.05) were independent predictive factors for post-PCI outcomes in patients with acute myocardial infarction. Kaplan-Meier method revealed a significant association between low JUP expression and adverse prognosis in AMI patients ( < 0.05). ROC curve showed that multi-vessel disease (AUC = 0.6548, Sensitivity = 64.29%, Specificity = 66.67%), TnI (AUC = 0.8316, Sensitivity = 40.71%, Specificity = 91.67%), and myocardial JUP (AUC = 0.8299, Sensitivity = 75.00%, Specificity = 84.29%) could all predict the risk of major adverse cardiac events (MACE) after PCI in AMI patients.

CONCLUSION

The expression level of JUP is decreased in patients with acute myocardial infarction and is closely associated with adverse prognostic outcomes. JUP may serve as a potential biomarker for assessing prognosis in AMI patients, providing new insights for the development of personalized treatment strategies.